October 25, 2021
National African American Multiple Sclerosis Registry: Advancing Equitable Care and Outcomes for African Americans with Multiple Sclerosis
Background: Historically, multiple sclerosis (MS) has been underdiagnosed among African Americans with MS (AAwMS). Recent evidence suggests...
Poster-Epidemiology and Genetics
October 25, 2021
Baseline Cognitive Impairment in Relapsing-Remitting Multiple Sclerosis Patients Enrolling in the US-Based Corrona MS Registry
Background: An estimated 85% of persons with multiple sclerosis (MS) present with relapsing-remitting (RRMS) disease. There are few large...
October 25, 2021
Could Cerebral Autoregulatory Collapse Explain Cognitive Impairment in MS?
Background: Cognitive impairment occurs in almost 70% of multiple sclerosis (MS) patients. The pathophysiology of this impairment is...
October 25, 2021
Prefrontal Metabolism Is Associated with Processing Speed in Multiple Sclerosis: A Calibrated fMRI Study
Background: Cognitive processing speed deficits are common in multiple sclerosis (MS). Despite this, the exact neural mechanism underlying...
Poster-Disease-modifying Therapy
October 25, 2021
Safety of Evobrutinib in Patients with Relapsing Multiple Sclerosis Is Maintained in a Long-Term Open-Label Extension of a Phase II Study
Background: In a 48-week Phase II study NCT02975349, in patients with relapsing multiple sclerosis, evobrutinib was generally...
Poster-Disease-modifying Therapy
October 25, 2021
The Benefits of Azathioprine in Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease: A Systematic Review and Meta-Analysis
Background: MOGAD is an emerging inflammatory demyelination disorder of the central nervous system. AZA is one of the commonly used...
Poster-Disease-modifying Therapy
October 25, 2021
Olikos Study Design: Exploring Maintained Ofatumumab Efficacy in Relapsing MS Patients Who Transition from Intravenous Anti-CD20 Therapy
Background: B-cell depletion in patients with relapsing multiple sclerosis (RMS) using anti-CD20 monoclonal antibodies (mAbs) reduces...
Poster-Disease-modifying Therapy
October 25, 2021
Real-World Safety and Effectiveness of Delayed-Release Dimethyl Fumarate in Relapsing Multiple Sclerosis Patients: Interim Results from Esteem
Background: Dimethyl fumarate (DMF) demonstrated strong efficacy and a favorable benefitrisk profile in patients with relapsing-remitting...
Poster-Disease-modifying Therapy
October 25, 2021
Characterization of Peripheral Immune Cell Dynamics and Repopulation Patterns in the First 12 Months of Cladribine Tablets Treatment: Magnify-MS Study
Background: The action of cladribine tablets (CladT) on immune cells may be key for both onset and durability of its effect in people with...
Poster-Disease-modifying Therapy
October 25, 2021
Immunoglobulin Kinetics and Infection Risk after Long-Term Inebilizumab Treatment for Neuromyelitis Optica Spectrum Disorder
Background: Long-term use of B-cell depleting monoclonal antibodies is associated with reduced immunoglobulin (Ig) levels that can...